We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Aimmune has announced the results from its Phase III European clinical trials for AR101, the company’s investigational oral biologic drug designed to help protect patients from severe allergic reactions in case they are accidentally exposed to peanut.